Xu Jing, Wang Yao-Hui, Xia Jing-Lin, Ge Ning-Ling, Chen Yi, Ye Sheng-Long
Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ai Zheng. 2009 May;28(5):520-3.
Systemic chemotherapy would suppress the immune system and cause reactivation of hepatitis B virus (HBV) in the tumor patients with HBV infection, which seriously affect the prognosis. Our study was to investigate the effect of transcatheter arterial chemoembolization (TACE) on HBV DNA level in primary liver cancer patients, and explore related factors.
Clinical data of 162 patients with primary liver cancer who underwent TACE from December 2004 to July 2008 were analyzed. All patients' HBV DNA level, alpha-fetoprotein (AFP) and liver function before and after TACE were evaluated. Correlation of HBV DNA alteration to AFP was analyzed.
The positive rate of HBV DNA was decreased significantly after TACE (55.6% vs. 71.6%, P<0.01). HBV DNA level was inclined to decrease after TACE in the patients with HBV DNA of > or =1 x 10(5)/mL (odds ratio = 2.7, P<0.01). The decrease of HBV DNA was also related with the decrease of AFP level (odds ratio = 2.6,P<0.05).
TACE can decrease HBV DNA level in primary liver cancer patients, especially for those with preoperative HBV DNA level of > or =1 x 10(5)/mL and those with postoperative AFP decline.
全身化疗会抑制免疫系统，并导致乙肝病毒（HBV）感染的肿瘤患者体内乙肝病毒再激活，这严重影响预后。我们的研究旨在探讨经动脉化疗栓塞术（TACE）对原发性肝癌患者HBV DNA水平的影响，并探索相关因素。
分析2004年12月至2008年7月期间接受TACE治疗的162例原发性肝癌患者的临床资料。评估所有患者TACE术前、术后的HBV DNA水平、甲胎蛋白（AFP）及肝功能。分析HBV DNA改变与AFP的相关性。
TACE术后HBV DNA阳性率显著降低（55.6%对71.6%，P<0.01）。术前HBV DNA≥1×10⁵/mL的患者TACE术后HBV DNA水平倾向于降低（优势比=2.7，P<0.01）。HBV DNA的降低还与AFP水平的降低有关（优势比=2.6，P<0.05）。
TACE可降低原发性肝癌患者的HBV DNA水平，尤其对于术前HBV DNA≥1×10⁵/mL以及术后AFP下降的患者。
